Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention

Future Medicinal Chemistry

Volumn 6, Issue 12, 2014, Pages 1423-1437

  Butterworth, Sam ^a   Overduin, Michael ^a   Barr, Alastair J ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; PROTEIN TYROSINE PHOSPHATASE SPH 2 INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

BREAST CANCER; CHONDROMATOSIS; ENZYME SUBSTRATE; LEOPARD SYNDROME; LEUKEMIA; METACHONDROMATOSIS; NOONAN SYNDROME; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CONFORMATION; DOSE RESPONSE; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MOLECULAR CONFORMATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84908129550     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/FMC.14.88     Document Type: Review

References (116)

1. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21(2), 140-146 (2009).
2. Pao LI, Badour K, Siminovitch KA, Neel BG. Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu. Rev. Immunol. 25, 473-523 (2007).
3. Paul S, Lombroso PJ. Receptor and nonreceptor protein tyrosine phosphatases in the nervous system. Cell. Mol. Life Sci. 60(11), 2465-2482 (2003).
4. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7(11), 833-846 (2006).
5. Alonso A, Sasin J, Bottini N et al. Protein tyrosine phosphatases in the human genome. Cell 117(6), 699-711 (2004).
6. Andersen JN, Mortensen OH, Peters GH et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. 21(21), 7117-7136 (2001).
7. Tautz L, Critton DA, Grotegut S. Protein tyrosine phosphatases: structure, function, and implication in human disease. Methods Mol. Biol. 1053, 179-221 (2013).
8. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell 139(3), 468-484 (2009).
9. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28(6), 284-293 (2003).
10. Chan RJ, Feng GS. PTPN11 is the first identified protooncogene that encodes a tyrosine phosphatase. Blood. 109(3), 862-867 (2007).
11. Deb TB, Wong L, Salomon DS et al. A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation. J. Biol. Chem. 273(27), 16643-16646 (1998).
12. Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 100(10), 1786-1793 (2009).
13. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92(4), 441-450 (1998).
14. Barr AJ, Ugochukwu E, Lee WH et al. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136(2), 352-363 (2009).
15. Yang J, Cheng Z, Niu T, Liang X, Zhao ZJ, Zhou GW. Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 275(6), 4066-4071 (2000).
16. Gu H, Neel BG. The "Gab" in signal transduction. Trends Cell Biol. 13(3), 122-130 (2003).
17. Stewart RA, Sanda T, Widlund HR et al. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev. Cell 18(5), 750-762 (2010).
18. Yu WM, Hawley TS, Hawley RG, Qu CK. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene 22(38), 5995-6004 (2003).
19. Lu W, Gong D, Bar-Sagi D, Cole PA. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell 8(4), 759-769 (2001).
20. Miura K, Wakayama Y, Tanino M et al. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Oncogene 32(45), 5292-5301 (2013).
21. Zheng H, Alter S, Qu CK. SHP-2 tyrosine phosphatase in human diseases. Int. J. Clin. Exp. Med. 2(1), 17-25 (2009).
22. Saxton TM, Henkemeyer M, Gasca S et al. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 16(9), 2352-2364 (1997).
23. Coulombe G, Leblanc C, Cagnol S et al. Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. Mol. Cell. Biol. 33(11), 2275-2284 (2013).
24. Mazharian A, Mori J, Wang YJ et al. Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function. Blood 121(20), 4205-4220 (2013).
25. Sharma N, Kumar V, Everingham S et al. SH2 domain-containing phosphatase 2 is a critical regulator of connective tissue mast cell survival and homeostasis in mice. Mol. Cell. Biol. 32(14), 2653-2663 (2012).
26. Bard-Chapeau EA, Yuan J, Droin N et al. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol. Cell. Biol. 26(12), 4664-4674 (2006).
27. Ke Y, Zhang EE, Hagihara K et al. Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol. Cell. Biol. 27(19), 6706-6717 (2007).
28. He Z, Zhang SS, Meng Q et al. Shp2 controls female body weight and energy balance by integrating leptin and estrogen signals. Mol. Cell. Biol. 32(10), 1867-1878 ( 2012).
29. Kontaridis MI, Yang W, Bence KK et al. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation 117(11), 1423-1435 (2008).
30. Ke Y, Lesperance J, Zhang EE et al. Conditional deletion of Shp2 in the mammary gland leads to impaired lobuloalveolar outgrowth and attenuated Stat5 activation. J. Biol. Chem. 281(45), 34374-34380 (2006).
31. Kim HK, Feng GS, Chen D, King PD, Kamiya N. Targeted disruption of shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions. J. Bone Miner. Res. 29(3), 761-769 (2014).
32. Bauler TJ, Kamiya N, Lapinski PE et al. Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations. Dis. Model. Mech. 4(2), 228-239 (2011).
33. Nguyen TV, Ke Y, Zhang EE, Feng GS. Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals. J. Immunol. 177(9), 5990-5996 (2006).
34. Zhang SS, Hao E, Yu J et al. Coordinated regulation by Shp2 tyrosine phosphatase of signaling events controlling insulin biosynthesis in pancreatic beta-cells. Proc. Natl Acad. Sci. USA 106(18), 7531-7536 (2009).
35. Li S, Hsu DD, Wang H, Feng GS. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front. Med. 6( 3), 275-279 (2012).
36. Bard-Chapeau EA, Li S, Ding J et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19(5), 629-639 (2011).
37. Yang W, Wang J, Moore DC et al. Ptpn11 deletion in a novel progenitor causes metach USA. ondromatosis by inducing hedgehog signalling. Nature 499(7459), 491-495 (2013).
38. + T cells promotes melanoma progression and metastasis. Sci. Rep. 3, 2845 (2013).
39. Sastry SK, Elferink LA. Checks and balances: interplay of RTKs and PTPs in cancer progression. Biochem. Pharmacol. 82(5), 435-440 (2011).
40. Tiganis T, Bennett AM. Protein tyrosine phosphatase function: the substrate perspective. Biochem. J. 402(1), 1-15 (2007).
41. Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell. Biol. 23(21), 7875-7886 (2003).
42. Agazie YM, Hayman MJ. Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates. J. Biol. Chem. 278(16), 13952-13958 (2003).
43. Montagner A, Yart A, Dance M, Perret B, Salles JP, Raynal P. A novel role for Gab1 and SHP2 in epidermal growth factorinduced Ras activation. J. Biol. Chem. 280(7), 5350-5360 (2005).
44. Zhang SQ, Yang W, Kontaridis MI et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 13(3), 341-355 (2004).
45. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27(2), 179-192 (2008).
46. Tartaglia M, Mehler EL, Goldberg R et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29(4), 465-468 (2001).
47. Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 6, 45-68 (2005).
48. Choong K, Freedman MH, Chitayat D, Kelly EN, Taylor G, Zipursky A. Juvenile myelomonocytic leukemia and Noonan syndrome. J. Pediatr. Hematol. Oncol. 21(6), 523-527 (1999).
49. Schubbert S, Bollag G, Lyubynska N et al. Biochemical and functional characterization of germ line KRAS mutations. Mol. Cell. Biol. 27(22), 7765-7770 (2007).
50. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J. Rare Dis. 3, 13 (2008).
51. Mali RS, Chan R, Kapur R. Targeting SHP2 phosphatase in myeloproliferative neoplasms. Oncotarget 3(10), 1049-1051 (2012).
52. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br. J. Haematol. 121(5), 758-767 (2003).
53. Keilhack H, David FS, Mcgregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem. 280(35), 30984-30993 (2005).
54. Schubbert S, Lieuw K, Rowe SL et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106(1), 311-317 (2005).
55. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281(10), 6785-6792 (2006).
56. Yu ZH, Xu J, Walls CD et al. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J. Biol. Chem. 288(15), 10472-10482 (2013).
57. Qiu W, Wang X, Romanov V et al. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct. Biol. 14(1), 10 (2014).
58. Kitayama H, Kanakura Y, Furitsu T et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factordependent hematopoietic cell lines. Blood 85(3), 790-798 (1995).
59. Munugalavadla V, Sims EC, Borneo J, Chan RJ, Kapur R. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood 110(5), 1612-1620 (2007).
60. Mali RS, Ma P, Zeng LF et al. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood 120(13), 2669-2678 (2012).
61. Bentires-Alj M, Paez JG, David FS et al. Activating mutations of the noonan syndrome-associated SHP2/ PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64(24), 8816-8820 (2004).
62. Eccles SA, Aboagye EO, Ali S et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 15(5), R92 (2013).
63. Bentires-Alj M, Gil SG, Chan R et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat. Med. 12(1), 114-121 (2006).
64. Bocanegra M, Bergamaschi A, Kim YH et al. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 29(5), 774-779 (2010).
65. Zhou X, Coad J, Ducatman B, Agazie YM. SHP2 is upregulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 53(4), 389-402 (2008).
66. Aceto N, Sausgruber N, Brinkhaus H et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat. Med. 18(4), 529-537 (2012).
67. Aceto N, Bentires-Alj M. Targeting protein-tyrosine phosphatases in breast cancer. Oncotarget 3(5), 514-515 (2012).
68. Boyle P, Levin B; International Agency for Research on Cancer. World Health Organization. World Cancer Report . IARC Press, France (2008).
69. Hatakeyama M, Higashi H. Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci. 96(12), 835-843 (2005).
70. Bowen ME, Boyden ED, Holm IA et al. Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet. 7(4), e1002050 (2011).
71. Sobreira NL, Cirulli ET, Avramopoulos D et al. Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet. 6(6), e1000991 (2010).
72. Martinelli S, Carta C, Flex E et al. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet. Cytogenet. 166(2), 124-129 (2006).
73. Miyamoto D, Miyamoto M, Takahashi A et al. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 27(25), 3508-3515 (2008).
74. Pugh TJ, Morozova O, Attiyeh EF et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45(3), 279-284 (2013).
75. Jones DT, Hutter B, Jager N et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45(8), 927-932 (2013).
76. Vintonyak VV, Antonchick AP, Rauh D, Waldmann H. The therapeutic potential of phosphatase inhibitors. Curr. Opin. Chem. Biol. 13(3), 272-283 (2009).
77. Combs AP: Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J. Med. Chem. 53(6), 2333-2344 (2010).
78. Barr AJ. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med. Chem. 2(10), 1563-1576 (2010).
79. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105(1), 3-7 (2000).
80. Yang J, Liang X, Niu T, Meng W, Zhao Z, Zhou GW. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 273(43), 28199-28207 (1998).
81. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 10(4), 356-360 (2009).
82. Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 167(6), 3391-3397 (2001).
83. Chen L, Sung SS, Yip ML et al. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol. 70(2), 562-570 (2006)
84. Lawrence HR, Pireddu R, Chen L et al. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J. Med. Chem. 51(16), 4948-4956 (2008).
85. Chen L, Pernazza D, Scott LM et al. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochem. Pharmacol. 80(6), 801-810 (2010).
86. Noren-Muller A, Reis-Correa I Jr, Prinz H et al. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl Acad. Sci. USA 103(28), 10606-10611 (2006).
87. Hellmuth K, Grosskopf S, Lum CT et al. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by highthroughput docking. Proc. Natl Acad. Sci. USA 105(20), 7275-7280 (2008).
88. Zhang X, He Y, Liu S et al. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J. Med. Chem. 53(6), 2482-2493 (2010).
89. Scott LM, Chen L, Daniel KG et al. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorg. Med. Chem. Lett. 21(2), 730-733 (2011).
90. Geronikaki A, Eleftheriou P, Vicini P, Alam I, Dixit A, Saxena AK. 2-thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action. J. Med. Chem. 51(17), 5221-5228 (2008).
91. Yu B, Liu W, Yu WM et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Mol. Cancer Ther. 12(9), 1738-1748 (2013).
92. Yu WM, Guvench O, Mackerell AD, Qu CK. Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay. J. Med. Chem. 51(23), 7396-7404 (2008).
93. Liu W, Yu B, Xu G et al. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J. Med. Chem. 56(18), 7212-7221 (2013).
94. Kundu S, Fan K, Cao M et al. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J. Immunol. 184(11), 6529-6536 (2010).
95. Liu S, Yu Z, Yu X et al. SHP2 is a target of the immunosuppressant tautomycetin. Chem. Biol. 18(1), 101-110 (2011).
96. Gobert RP, Van Den Eijnden M, Szyndralewiez C et al. GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis. J. Biol. Chem. 284(17), 11385-11395 (2009).
97. He Y, Liu S, Menon A et al. A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases. J. Med. Chem. 56(12), 4990-5008 (2013).
98. Frezard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 14(7), 2317-2336 (2009).
99. Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169(10), 5978-5985 (2002).
100. Yi T, Elson P, Mitsuhashi M et al. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget 2(12), 1155-1164 (2011).
101. Clinicaltrials.gov. Search results for 'stibogluconate OR MSI-1436'. www.clinicaltrials.gov/ct2/results?term=stibogluconate+OR+MSI-1436
102. Song M, Park JE, Park SG et al. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem. Biophys. Res. Commun. 381(4), 491-495 (2009).
103. Luo Q, Sun Y, Gong FY et al. Blocking initial infiltration of pioneer CD8 T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice. Br. J. Pharmacol. 171(7), 1706-1721 (2014).
104. Schramm C, Edwards MA, Krenz M. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling. J. Biol. Chem. 288(25), 18335-18344 (2013).
105. Xu J, Zeng LF, Shen W, Turchi JJ, Zhang ZY. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. Biochem. Biophys. Res. Commun. 439(4), 586-590 (2013).
106. Ravery V, Fizazi K, Oudard S et al. The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int. 108(11), 1782-1786 (2011).
107. Bergenheim AT, Henriksson R. Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin. Pharmacokinet. 34(2), 163-172 (1998).
108. Krishnan N, Koveal D, Miller DH et al. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat. Chem. Biol. 10(7), 558-566 (2014).
109. Wang Q, Dube D, Friesen RW et al. Catalytic inactivation of protein tyrosine phosphatase CD45 and protein tyrosine phosphatase 1B by polyaromatic quinones. Biochemistry 43(14), 4294-4303 (2004).
110. Cheng XC, Kihara T, Ying X et al. A new antibiotic, tautomycetin. J. Antibiot. (Tokyo) 42(1), 141-144 (1989).
111. Mitsuhashi S, Matsuura N, Ubukata M, Oikawa H, Shima H, Kikuchi K. Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PP1. Biochem. Biophys. Res. Commun. 287(2), 328-331 (2001).
112. Han DJ, Jeong YL, Wee YM et al. Tautomycetin as a novel immunosuppressant in transplantation. Transplant. Proc. 35(1), 547 (2003).
113. Shim JH, Lee HK, Chang EJ et al. Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction. Proc. Natl Acad. Sci. USA 99(16), 10617-10622 (2002).
114. Lee JH, Lee JS, Kim SE et al. Tautomycetin inhibits growth of colorectal cancer cells through p21cip/WAF1 induction via the extracellular signal-regulated kinase pathway. Mol. Cancer Ther. 5(12), 3222-3231 (2006).
115. Niu M, Sun Y, Liu X, Tang L, Qiu R. Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells. J. Pharmacol. Sci. 121(1), 17-24 (2013).
116. Niu M, Sun Y, Liu B, Tang L, Qiu R. Differential effects of tautomycetin and its derivatives on protein phosphatase inhibition, immunosuppressive function and antitumor activity. Korean J. Physiol. Pharmacol. 16(2), 145-151 (2012).